Support with the BVS 5000 assist device during treatment of acute giant-cell myocarditis.

Giant-cell myocarditis is a rare and aggressive form of myocarditis with a high mortality rate. Our purpose is to summarize 3 cases of acute giant-cell myocarditis that illustrate possible outcomes with mechanical support. We reviewed the cases of 3 patients, aged 39 to 59 years, who had giant-cell myocarditis (confirmed by myocardial biopsy). The indication for ventricular assist was circulatory failure despite maximal medical treatment with 2 or more inotropic agents and intraaortic balloon pump support. Immunosuppression and a biventricular mechanical assist (BVS 5000) were used to treat all these patients. The mean duration of mechanical support was 15.7 days (range, 10 to 19 days). One patient had recovery of myocardial function and was weaned from mechanical support. This case is, to our knowledge, the first reported of ventricular support leading to cardiac recovery after diagnosis of giant-cell myocarditis. The 2nd patient was not a candidate for further surgery and died of multisystem organ failure. The 3rd patient underwent orthotopic heart transplantation after 18 days of support and was discharged. We conclude that patients with giant-cell myocarditis tend to have biventricular involvement and can recover myocardial function on mechanical support and immunosuppression. If recovery is not observed, transplantation is warranted. By avoiding left ventricular cannulation, the BVS 5000 is well suited for bridging to recovery, transplantation, or long-term support.

[1]  J. Kobashigawa,et al.  Short‐Term Bridge to Heart Transplant Using the BVS 5000 External Ventricular Assist Device 1, 2 , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  G. Berry,et al.  Survival Outcomes of Patients with Giant Cell Myocarditis Bridged by Ventricular Assist Devices , 2000, ASAIO journal.

[3]  G. Fonarow,et al.  Mechanical assist strategy using the BVS 5000i for patients with heart failure. , 2000, The Annals of thoracic surgery.

[4]  R. Hruban,et al.  Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. , 2000, The New England journal of medicine.

[5]  M. Pieroni,et al.  Giant cell myocarditis responding to immunosuppressive therapy. , 2000, Chest.

[6]  G. Berry,et al.  Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. , 1997, The New England journal of medicine.

[7]  G. Couper,et al.  Temporary Mechanical Support with the BVS 5000 Assist Device During Treatment of Acute Myocarditis , 1997 .

[8]  G. Jett ABIOMED BVS 5000: experience and potential advantages. , 1996, The Annals of thoracic surgery.

[9]  M. Kodama,et al.  Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. , 1994, Circulation research.

[10]  M. Nieminen,et al.  Treatment of serious heart failure by transplantation in giant cell myocarditis diagnosed by endomyocardial biopsy. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  G. Winters,et al.  Giant cell myocarditis: first report of disease recurrence in the transplanted heart. , 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  J. Ninet,et al.  Use of the Abiomed BVS System 5000 as a bridge to cardiac transplantation. , 1990, The Journal of thoracic and cardiovascular surgery.